Anti-FGF19 Antibody

By developing an N-terminal antibody specifically targeting FGF19, the bile acid metabolism disorders and side effects caused by existing antibodies in the treatment of HCC were solved, and effective treatment of HCC was achieved and the normal function of bile acid regulation was maintained.

CN113710701BActive Publication Date: 2025-02-28HUAHUI HEALTH LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202080012196.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-02-02
Filing Date
2020-02-02
Publication Date
2025-02-28
Estimated Expiration
2040-02-02

AI Technical Summary

Technical Problem

Existing antibodies targeting FGF19 may lead to bile acid metabolism disorders and severe side effects such as weight loss, diarrhea and low food consumption when treating hepatocellular carcinoma (HCC).

Method used

An antibody specifically targeting the N-terminal of FGF19 is developed that blocks abnormal FGF19/FGFR4 signaling by specifically binding to the N-terminal of FGF19 without affecting the normal function of FGF19 in bile acid regulation.

Benefits of technology

The antibody showed strong anti-tumor activity and had significant therapeutic effects on HCC, while avoiding the negative impact on bile acid metabolism and reducing the occurrence of side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003192171600000295
    Figure BDA0003192171600000295
  • Figure BDA0003192171600000301
    Figure BDA0003192171600000301
  • Figure BDA0003192171600000311
    Figure BDA0003192171600000311
Patent Text Reader

Abstract

The present invention provides an anti-FGF-19 antibody and an antigen-binding fragment thereof that selectively targets the N-terminus of fibroblast growth factor 19 (FGF19). Also provided are compositions and uses of the antibodies, and methods for treating diseases or conditions caused by or associated with abnormal FGF19-FGFR4 signaling, such as cancer, by administering the anti-FGF-19 antibodies.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Halogenated pyranthrone and process of making same

    US1975256A

  • Immunometric assays using monoclonal antibodies

    US4376110A

  • Arthur liebrecht

    US495497A

  • Anti-FGF19 antibodies and methods using same

    WO2007136893A2

  • Anti-il 17a / il-17f cross-reactive antibodies and methods of use thereof

    CN104628855A